Investor Presentaiton

Q2 2023 SUMMARY Lilly • Excluding COVID-19 antibodies and Baqsimi, revenue grew 22%, driven by 23% volume growth • Continued to speed life-changing medicines to patients with: • Positive results in the Phase 3 TRAILBLAZER-ALZ 2 study and the submission of donanemab for traditional approval to the FDA; • The completed submission of tirzepatide in chronic weight management to the FDA and SURMOUNT-3 and SURMOUNT-4 positive topline results; and • The approval of mirikizumab in the EU and re-submission in the U.S. • Announced several acquisitions and deployed over $1 billion to shareholders via the dividend Q2 investment growth driven by investments in new products and indications and late-stage pipeline Not for promotional use Invest in Current Portfolio Invest in Future Innovation Deliver Revenue Growth R Speed Life-Changing Medicines Return Capital to Shareholders 2023 Q2 EARNINGS 20 20

View entire presentation